A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety and tolerability of the study drug HBM4003, and to
determine the maximum tolerated dose and/or recommended Phase 2 study dose of HBM4003. The
study will also look at the anti-tumor activity of HBM4003.The study consists of 2 parts. In
Part 1, patients are enrolled into different cohort doses in order to identify the
appropriate recommended phase 2 dose (RP2D) or maximum tolerated dose (MTD). In Part 2,
participants with metastatic/unresectable melanoma will receive the MTD and/or RP2D
established in Part 1 of the study. In Part 1 and Part 2, participants will be administered
treatment either once per week or once every 3 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Harbour BioMed (Guangzhou) Co. Ltd. Harbour BioMed US, Inc.